IN2012DN00971A - - Google Patents
Info
- Publication number
- IN2012DN00971A IN2012DN00971A IN971DEN2012A IN2012DN00971A IN 2012DN00971 A IN2012DN00971 A IN 2012DN00971A IN 971DEN2012 A IN971DEN2012 A IN 971DEN2012A IN 2012DN00971 A IN2012DN00971 A IN 2012DN00971A
- Authority
- IN
- India
- Prior art keywords
- adrenoceptor
- activation
- prevention
- formula
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23748709P | 2009-08-27 | 2009-08-27 | |
| PCT/US2010/046468 WO2011025774A1 (en) | 2009-08-27 | 2010-08-24 | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00971A true IN2012DN00971A (en10) | 2015-04-10 |
Family
ID=43628346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN971DEN2012 IN2012DN00971A (en10) | 2009-08-27 | 2010-08-24 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8604038B2 (en10) |
| EP (1) | EP2470012B1 (en10) |
| JP (1) | JP5671538B2 (en10) |
| CN (1) | CN102573471B (en10) |
| AU (1) | AU2010286694B2 (en10) |
| BR (1) | BR112012004333A2 (en10) |
| CA (1) | CA2770475C (en10) |
| IN (1) | IN2012DN00971A (en10) |
| MX (1) | MX2012002366A (en10) |
| WO (1) | WO2011025774A1 (en10) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011279845B8 (en) | 2010-07-23 | 2014-11-20 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| TW201208667A (en) | 2010-08-03 | 2012-03-01 | Altherx Inc | Pharmaceutical combinations |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9486448B2 (en) | 2013-10-03 | 2016-11-08 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2969405A1 (en) | 2014-12-03 | 2016-06-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| US20180186755A1 (en) * | 2015-07-01 | 2018-07-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| NZ779968A (en) | 2015-09-14 | 2025-05-02 | Twelve Therapeutics Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| DK3365321T3 (da) | 2015-10-23 | 2024-01-15 | B3Ar Therapeutics Inc | Solabegron-zwitterion og anvendelser deraf |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10408983B2 (en) | 2016-08-16 | 2019-09-10 | Moxtek, Inc. | Durable, high performance wire grid polarizer having permeable junction between top protection layer |
| CN106831601A (zh) * | 2017-01-13 | 2017-06-13 | 河北博伦特药业有限公司 | 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法 |
| MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| EP3893892A4 (en) * | 2018-12-12 | 2022-09-14 | Rutgers, the State University of New Jersey | Organic compounds |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| GB202113588D0 (en) | 2021-09-23 | 2021-11-10 | Atrogi Ab | New compounds and methods |
| CN113816917B (zh) * | 2021-11-19 | 2022-02-18 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0071399A3 (en) * | 1981-07-22 | 1983-12-07 | Syntex (U.S.A.) Inc. | Substituted pyrrolidine cardiovascular system regulators and antihypertensives, their preparation and use |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| AU2009231967B2 (en) * | 2008-04-04 | 2013-02-07 | Merck Sharp & Dohme Corp. | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| WO2011025690A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
-
2010
- 2010-08-24 JP JP2012526908A patent/JP5671538B2/ja not_active Expired - Fee Related
- 2010-08-24 CA CA2770475A patent/CA2770475C/en not_active Expired - Fee Related
- 2010-08-24 AU AU2010286694A patent/AU2010286694B2/en not_active Ceased
- 2010-08-24 IN IN971DEN2012 patent/IN2012DN00971A/en unknown
- 2010-08-24 MX MX2012002366A patent/MX2012002366A/es active IP Right Grant
- 2010-08-24 BR BR112012004333A patent/BR112012004333A2/pt not_active Application Discontinuation
- 2010-08-24 EP EP10812548.5A patent/EP2470012B1/en not_active Not-in-force
- 2010-08-24 CN CN201080037958.8A patent/CN102573471B/zh not_active Expired - Fee Related
- 2010-08-24 US US13/392,282 patent/US8604038B2/en active Active
- 2010-08-24 WO PCT/US2010/046468 patent/WO2011025774A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010286694B2 (en) | 2013-09-12 |
| WO2011025774A1 (en) | 2011-03-03 |
| CN102573471A (zh) | 2012-07-11 |
| EP2470012A1 (en) | 2012-07-04 |
| JP2013503167A (ja) | 2013-01-31 |
| CN102573471B (zh) | 2014-11-26 |
| BR112012004333A2 (pt) | 2015-09-08 |
| AU2010286694A1 (en) | 2012-03-08 |
| EP2470012B1 (en) | 2014-11-05 |
| MX2012002366A (es) | 2012-03-29 |
| CA2770475C (en) | 2017-06-27 |
| US20120225886A1 (en) | 2012-09-06 |
| JP5671538B2 (ja) | 2015-02-18 |
| CA2770475A1 (en) | 2011-03-03 |
| US8604038B2 (en) | 2013-12-10 |
| EP2470012A4 (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00971A (en10) | ||
| IN2014CN04907A (en10) | ||
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| IN2012DN03883A (en10) | ||
| PH12014500053A1 (en) | Proteasome inhibitors | |
| MY151246A (en) | Benzofuranyl derivatives | |
| MX2012000565A (es) | Derivados de triterpeno tipo lupeol como antivirales. | |
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| GB201118656D0 (en) | New compounds | |
| MX364200B (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| UA103915C2 (ru) | Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение | |
| UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
| IN2012MN02591A (en10) | ||
| MX2012006730A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas. | |
| DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
| TN2011000647A1 (en) | Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria | |
| MX2012003644A (es) | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. | |
| MY153766A (en) | Derivatised proline containing peptide organic compounds as protease inhibitors | |
| MX2011013577A (es) | Composiciones y metodos para tratar esclerosis lateral amiotrofica. | |
| MX2012004780A (es) | Inhibidores de akt. | |
| IN2012DN02471A (en10) | ||
| MY164354A (en) | Asymmetric ureas and medical uses thereof |